Literature DB >> 1906071

Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum.

C R Tillyer1, J Iqbal, J Raymond, M Gore, T J McIlwain.   

Abstract

An immunoturbidimetric assay for the assessment of free kappa and lambda light chains of immunoglobulins was developed using a commercial polyclonal antiserum with reactivity towards epitopes on the light chains, which are not expressed when they are bound to heavy chains. The assay, on a centrifugal analyser, is simple and rapid. The limit of detection is 5 mg/l of free light chain, with an assay range of 5-120 mg/l, intrabatch precisions from 1.5-6.4%, and interbatch precisions from 6.5-8.9%. The assay was only slightly less sensitive than colloidal gold staining of cellulose acetate electrophoreses for the detection of Bence-Jones protein in urine. For the serial monitoring of response to chemotherapy in patients with myeloma, the assay correlated well with serum paraprotein estimates obtained by densitometric scanning of Ponceau stained cellulose acetate electrophoreses, but not with serum beta-2 microglobulin measurements, even after correction for the effects of creatinine. These assays may prove to be of use for the monitoring of tumour response in the treatment of Bence-Jones myeloma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906071      PMCID: PMC496826          DOI: 10.1136/jcp.44.6.466

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  21 in total

1.  Paraprotein estimation: a comparison of immunochemical and densitometric techniques.

Authors:  A M Smith; R A Thompson
Journal:  J Clin Pathol       Date:  1978-12       Impact factor: 3.411

Review 2.  Low molecular weight proteinuria.

Authors:  C L Hall; J Hardwicke
Journal:  Annu Rev Med       Date:  1979       Impact factor: 13.739

3.  Immunologic methods for detection and quantification of Bence Jones proteins.

Authors:  L Zelkowitz; V Yakulis
Journal:  J Lab Clin Med       Date:  1970-12

4.  Free light chains of immunoglobulins in normal serum and urine determined by radioimmunoassay.

Authors:  K Sölling
Journal:  Scand J Clin Lab Invest       Date:  1975-09       Impact factor: 1.713

5.  Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.

Authors:  R Bataille; J Grenier; J Sany
Journal:  Blood       Date:  1984-02       Impact factor: 22.113

6.  Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma.

Authors:  B G Durie; P W Cole; H S Chen; K J Himmelstein; S E Salmon
Journal:  Br J Haematol       Date:  1981-01       Impact factor: 6.998

7.  Immunoquantitation of free light chain immunoglobulins: applications in multiple myeloma.

Authors:  P W Cole; B G Durie; S E Salmon
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

8.  Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.

Authors:  J H Scarffe; H Anderson; M K Palmer; D Crowther
Journal:  Eur J Cancer Clin Oncol       Date:  1983-10

9.  A cellulose acetate immunofixation technique.

Authors:  J Kohn; P G Riches
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

10.  Misonidazole and MTDQ in combination: cytotoxic and radiosensitizing properties in hypoxic mammalian cells.

Authors:  M Astor; E J Hall
Journal:  Br J Cancer       Date:  1979-05       Impact factor: 7.640

View more
  2 in total

1.  Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.

Authors:  Troy D Jaskowski; Christine M Litwin; Harry R Hill
Journal:  Clin Vaccine Immunol       Date:  2006-02

2.  Differences in kappa to lambda (kappa:lambda) ratios of serum and urinary free light chains.

Authors:  M Abe; T Goto; M Kosaka; D Wolfenbarger; D T Weiss; A Solomon
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.